Swiss National Bank Makes New Investment in Rapport Therapeutics (NASDAQ:RAPP)

Swiss National Bank bought a new stake in shares of Rapport Therapeutics (NASDAQ:RAPP) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 18,000 shares of the company’s stock, valued at approximately $319,000.

Several other large investors also recently modified their holdings of RAPP. New York State Common Retirement Fund bought a new position in shares of Rapport Therapeutics during the 4th quarter worth $62,000. Jennison Associates LLC purchased a new stake in Rapport Therapeutics during the fourth quarter valued at about $1,105,000. China Universal Asset Management Co. Ltd. bought a new position in Rapport Therapeutics during the fourth quarter worth about $138,000. JPMorgan Chase & Co. purchased a new position in shares of Rapport Therapeutics in the third quarter worth about $83,000. Finally, Barclays PLC raised its position in shares of Rapport Therapeutics by 36.8% in the third quarter. Barclays PLC now owns 12,863 shares of the company’s stock valued at $264,000 after purchasing an additional 3,463 shares during the period.

Insiders Place Their Bets

In related news, Director Wendy B. Young acquired 6,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The shares were bought at an average cost of $10.21 per share, for a total transaction of $61,260.00. Following the purchase, the director now owns 6,000 shares in the company, valued at $61,260. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Troy A. Ignelzi bought 9,900 shares of the business’s stock in a transaction on Wednesday, March 12th. The stock was bought at an average price of $10.10 per share, with a total value of $99,990.00. Following the purchase, the chief financial officer now owns 9,900 shares in the company, valued at $99,990. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here.

Rapport Therapeutics Trading Up 3.6 %

Shares of RAPP stock opened at $10.05 on Monday. Rapport Therapeutics has a 12 month low of $6.43 and a 12 month high of $29.74. The stock has a market capitalization of $366.78 million and a P/E ratio of -0.73. The firm’s 50 day moving average is $12.54 and its 200 day moving average is $17.98.

Rapport Therapeutics Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.